Roche is set to acquire PathAI, a digital pathology company, in a deal that could exceed $1 billion. The acquisition aims to bolster Roche's capabilities in cancer diagnostics and tailored therapies by integrating PathAI's artificial intelligence-powered tools.
PathAI specializes in using machine learning to analyze pathology images, helping pathologists detect cancer cells more accurately and efficiently. Its platforms are designed to support drug development and clinical diagnostics, with potential to improve patient outcomes through precision medicine.